Natural killer cells require monocytic Gr-1+/CD11b+ myeloid cells to eradicate orthotopically engrafted glioma cells

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Baker, Gregory J ^a   Chockley, Peter ^a   Zamler, Daniel ^a   Castro, Maria G ^a   Lowenstein, Pedro R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

gal 1 deficient glioma; Galectin 1 (gal 1); GL26; Gr 1+ CD11b+ myeloid cells; natural killer (NK) cells

Indexed keywords

CD11B ANTIGEN; GALECTIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BONE MARROW CELL; CANCER TRANSPLANTATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; GLIOMA CELL; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; KAPLAN MEIER METHOD; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RAG1-/- MOUSE; TUMOR MICROENVIRONMENT;

EID: 84973169046     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1163461     Document Type: Article

References (55)

1. Q.T.Ostrom, H.Gittleman, P.Liao, C.Rouse, Y.Chen, J.Dowling, Y.Wolinsky, C.Kruchko, J.Barnholtz-Sloan. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014; 16 Suppl 4:iv1-63; PMID:25304271; 10.1093/neuonc/nou223
2. A.Waziri Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 2010; 21:31-42; PMID:19944964; 10.1016/j.nec.2009.08.005
3. M.Hegde, K.J.Bielamowicz, N.Ahmed. Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med 2014; 17:145-54; PMID:24641957
4. M.Weller Immunotherapy for glioblastoma: a long and winding road. Neuro Oncol 2010; 12:319; PMID:20308309; 10.1093/neuonc/noq027
5. S.Ostrand-Rosenberg, P.Sinha. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; 10.4049/jimmunol.0802740
6. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; 10.1038/nri2506
7. B.Raychaudhuri, P.Rayman, J.Ireland, J.Ko, B.Rini, E.C.Borden, J.Garcia, M.A.Vogelbaum, J.Finke. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13:591-9; PMID:21636707; 10.1093/neuonc/nor042
8. G.Kohanbash, H.Okada. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest 2012; 41:658-79; PMID:23017140; 10.3109/08820139.2012.689591
9. S.Kusmartsev, D.I.Gabrilovich. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237-45; PMID:16047143; 10.1007/s00262-005-0048-z
10. P.C.Rodriguez, A.C.Ochoa. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; PMID:18364002; 10.1111/j.1600-065X.2008.00608.x
11. S.Nagaraj, K.Gupta, V.Pisarev, L.Kinarsky, S.Sherman, L.Kang, D.L.Herber, J.Schneck, D.I.Gabrilovich. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; 10.1038/nm1609
12. J.Yu, W.Du, F.Yan, Y.Wang, H.Li, S.Cao, W.Yu, C.Shen, J.Liu, X.Ren. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190:3783-97; PMID:23440412; 10.4049/jimmunol.1201449
13. C.A.Corzo, M.J.Cotter, P.Cheng, F.Cheng, S.Kusmartsev, E.Sotomayor, T.Padhya, T.V.McCaffrey, J.C.McCaffrey, D.I.Gabrilovich. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; PMID:19380816; 10.4049/jimmunol.0900092
14. P.Sinha, V.K.Clements, S.K.Bunt, S.M.Albelda, S.Ostrand-Rosenberg. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83; PMID:17617589; 10.4049/jimmunol.179.2.977
15. H.Li, Y.Han, Q.Guo, M.Zhang, X.Cao. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182:240-9; PMID:19109155; 10.4049/jimmunol.182.1.240
16. M.Elkabets, V.S.Ribeiro, C.A.Dinarello, S.Ostrand-Rosenberg, J.P.Di Santo, R.N.Apte, C.A.Vosshenrich. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010; 40:3347-57; PMID:21110318; 10.1002/eji.201041037
17. K.Movahedi, M.Guilliams, J.Van den Bossche, R.Van den Bergh, C.Gysemans, A.Beschin, P.De Baetselier, J.A.Van Ginderachter. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; 10.1182/blood-2007-07-099226
18. J.I.Youn, S.Nagaraj, M.Collazo, D.I.Gabrilovich. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; 10.4049/jimmunol.181.8.5791
19. J.C.Rodrigues, G.C.Gonzalez, L.Zhang, G.Ibrahim, J.J.Kelly, M.P.Gustafson, Y.Lin, A.B.Dietz, P.A.Forsyth, V.W.Yong et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12:351-65; PMID:20308313; 10.1093/neuonc/nop023
20. M.Chae, T.E.Peterson, A.Balgeman, S.Chen, L.Zhang, D.N.Renner, A.J.Johnson, I.F.Parney. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol 2014; 17:978-91; PMID:25537019; 10.1093/neuonc/nou343
21. G.Kohanbash, K.McKaveney, M.Sakaki, R.Ueda, A.H.Mintz, N.Amankulor, M.Fujita, J.R.Ohlfest, H.Okada. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res 2013; 73:6413-23; PMID:24030977; 10.1158/0008-5472.CAN-12-4124
22. J.P.Zou, L.A.Morford, C.Chougnet, A.R.Dix, A.G.Brooks, N.Torres, J.D.Shuman, J.E.Coligan, W.H.Brooks, T.L.Roszman et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999; 162:4882-92; PMID:10202033
23. O.Bloch, C.A.Crane, R.Kaur, M.Safaee, M.J.Rutkowski, A.T.Parsa. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013; 19:3165-75; PMID:23613317; 10.1158/1078-0432.CCR-12-3314
24. M.P.Gustafson, Y.Lin, K.C.New, P.A.Bulur, B.P.O'Neill, D.A.Gastineau, A.B.Dietz. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010; 12:631-44; PMID:20179016; 10.1093/neuonc/noq001
25. A.Wu, J.Wei, L.Y.Kong, Y.Wang, W.Priebe, W.Qiao, R.Sawaya, A.B.Heimberger. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113-25; PMID:20667896; 10.1093/neuonc/noq082
26. L.A.Earl, S.Bi, L.G.Baum. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J Biol Chem 2010; 285:2232-44; PMID:19920154; 10.1074/jbc.M109.066191
27. N.L.Perillo, K.E.Pace, J.J.Seilhamer, L.G.Baum. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378:736-9; PMID:7501023; 10.1038/378736a0
28. N.Rubinstein, M.Alvarez, N.W.Zwirner, M.A.Toscano, J.M.Ilarregui, A.Bravo, J.Mordoh, L.Fainboim, O.L.Podhajcer, G.A.Rabinovich. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241-51; PMID:15050916; 10.1016/S1535-6108(04)00024-8
29. A.Banh, J.Zhang, H.Cao, D.M.Bouley, S.Kwok, C.Kong, Q.T.Le. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011; 71:4423-31; PMID:21546572; 10.1158/0008-5472.CAN-10-4157
30. R.Rostoker, H.Yaseen, S.Schif-Zuck, R.G.Lichtenstein, G.A.Rabinovich, A.Ariel. Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors their conversion toward a pro-resolving phenotype. Prostaglandins Other Lipid Mediat 2013; 107:85-94; PMID:23954858; 10.1016/j.prostaglandins.2013.08.001
31. S.C.Starossom, I.D.Mascanfroni, J.Imitola, L.Cao, K.Raddassi, S.F.Hernandez, R.Bassil, D.O.Croci, J.P.Cerliani, D.Delacour et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012; 37:249-63; PMID:22884314; 10.1016/j.immuni.2012.05.023
32. G.J.Baker, P.Chockley, V.N.Yadav, R.Doherty, M.Ritt, S.Sivaramakrishnan, M.G.Castro, P.R.Lowenstein. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res 2014; 74:5079-90; PMID:25038230; 10.1158/0008-5472.CAN-14-1203
33. C.A.Crane, K.Austgen, K.Haberthur, C.Hofmann, K.W.Moyes, L.Avanesyan, L.Fong, M.J.Campbell, S.Cooper, S.A.Oakes et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A 2014; 111:12823-8; PMID:25136121; 10.1073/pnas.1413933111
34. C.Shi, E.G.Pamer. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11:762-74; PMID:21984070; 10.1038/nri3070
35. G.J.Baker, V.N.Yadav, S.Motsch, C.Koschmann, A.A.Calinescu, Y.Mineharu, S.I.Camelo-Piragua, D.Orringer, S.Bannykh, W.S.Nichols et al. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 2014; 16:543-61; PMID:25117977; 10.1016/j.neo.2014.06.003
36. G.J.Baker, M.G.Castro, P.R.Lowenstein. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp. 2015 Nov 28; (105); PMID:26650233; 10.3791/53676
37. B.N.Jaeger, J.Donadieu, C.Cognet, C.Bernat, D.Ordonez-Rueda, V.Barlogis, N.Mahlaoui, A.Fenis, E.Narni-Mancinelli, B.Beaupain et al. Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. J Exp Med 2012; 209:565-80; PMID:22393124; 10.1084/jem.20111908
38. R.Sporri, N.Joller, H.Hilbi, A.Oxenius. A novel role for neutrophils as critical activators of NK cells. J Immunol 2008; 181:7121-30; PMID:18981133; 10.4049/jimmunol.181.10.7121
39. N.Nausch, I.E.Galani, E.Schlecker, A.Cerwenka. Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood 2008; 112:4080-9; PMID:18753637; 10.1182/blood-2008-03-143776
40. S.M.Soudja, A.L.Ruiz, J.C.Marie, G.Lauvau. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 2012; 37:549-62; PMID:22940097; 10.1016/j.immuni.2012.05.029
41. N.Dalbeth, R.Gundle, R.J.Davies, Y.C.Lee, A.J.McMichael, M.F.Callan. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173:6418-26; PMID:15528382; 10.4049/jimmunol.173.10.6418
42. N.Lapaque, T.Walzer, S.Meresse, E.Vivier, J.Trowsdale. Interactions between human NK cells and macrophages in response to Salmonella infection. J Immunol 2009; 182:4339-48; PMID:19299734; 10.4049/jimmunol.0803329
43. S.Nedvetzki, S.Sowinski, R.A.Eagle, J.Harris, F.Vely, D.Pende, J.Trowsdale, E.Vivier, S.Gordon, D.M.Davis. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007; 109:3776-85; PMID:17218381; 10.1182/blood-2006-10-052977
44. O.Atochina, D.Harn. LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin Diagn Lab Immunol 2005; 12:1041-9; PMID:16148169; 10.1128/CDLI.12.9.1041-1049.2005
45. O.Chijioke, C.Munz. Interactions of human myeloid cells with natural killer cell subsets in vitro and in vivo. J Biomed Biotechnol 2011; 2011:251679; PMID:21541250; 10.1155/2011/251679
46. M.Kijima, T.Yamaguchi, C.Ishifune, Y.Maekawa, A.Koyanagi, H.Yagita, S.Chiba, K.Kishihara, M.Shimada, K.Yasutomo. Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction. Proc Natl Acad Sci U S A 2008; 105:7010-5; PMID:18458347; 10.1073/pnas.0709919105
47. M.Schmitz, S.Zhao, Y.Deuse, K.Schakel, R.Wehner, H.Wohner, K.Hölig, F.Wienforth, A.Kiessling, M.Bornhäuser et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 2005; 174:4127-34; PMID:15778372; 10.4049/jimmunol.174.7.4127
48. D.Valteau-Couanet, C.Leboulaire, K.Maincent, M.Tournier, O.Hartmann, J.Benard, F.Beaujean, C.Boccaccio, L.Zitvogel, E.Angevin. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002; 100:2554-61; PMID:12239169; 10.1182/blood.V100.7.2554
49. A.Rivollier, J.He, A.Kole, V.Valatas, B.L.Kelsall. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012; 209:139-55; PMID:22231304; 10.1084/jem.20101387
50. S.Watanabe, K.Deguchi, R.Zheng, H.Tamai, L.X.Wang, P.A.Cohen, S.Shu. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008; 181:3291-300; PMID:18714001; 10.4049/jimmunol.181.5.3291
51. H.Shime, A.Kojima, A.Maruyama, Y.Saito, H.Oshiumi, M.Matsumoto, T.Seya. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 2014; 6:293-305; PMID:24192491; 10.1159/000355126
52. B.Thaci, A.U.Ahmed, I.V.Ulasov, D.A.Wainwright, P.Nigam, B.Auffinger, A.L.Tobias, Y.Han, L.Zhang, K.S.Moon et al. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther 2014; 21:38-44; PMID:24434573; 10.1038/cgt.2013.81
53. J.E.Talmadge, D.I.Gabrilovich. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; 10.1038/nrc3581
54. M.Le Mercier, F.Lefranc, T.Mijatovic, O.Debeir, B.Haibe-Kains, G.Bontempi, C.Decaestecker, R.Kiss, V.Mathieu. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008; 229:172-83; PMID:18313712; 10.1016/j.taap.2008.01.009
55. B.L.Mundy-Bosse, G.B.Lesinski, A.C.Jaime-Ramirez, K.Benninger, M.Khan, P.Kuppusamy, K.Guenterberg, S.V.Kondadasula, A.R.Chaudhury, K.M.La Perle et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011; 71:5101-10; PMID:21680779; 10.1158/0008-5472.CAN-10-2670